US stock futures muted as rate cut bets wane ahead of Jackson Hole
In a challenging market environment, Becton Dickinson and Co. (NYSE:BDX) stock has recorded a new 52-week low, dipping to $186.01. According to InvestingPro data, the company maintains a "GOOD" financial health score, with particularly strong profitability metrics and a beta of just 0.38, indicating lower volatility than the broader market. The medical technology company, known for its wide array of medical devices and supplies, has faced headwinds that have pressured its stock price over the past year, culminating in a significant retreat from its previous levels. Despite the challenges, the company has maintained its impressive 54-year streak of dividend increases, with a current yield of 2.01%. This latest price point marks a stark contrast to the stock’s performance over the past year, with Becton Dickinson experiencing a 1-year change of -13.84%, reflecting broader market trends and investor sentiment in the healthcare sector. InvestingPro analysis suggests the stock is currently trading below its Fair Value, potentially presenting an opportunity for value investors. As stakeholders and analysts review the implications of this new low, the company’s strategic responses and market conditions in the coming months will be closely monitored. With analyst targets ranging from $245 to $325 and expected net income growth this year, detailed analysis and additional insights are available in the comprehensive Pro Research Report on InvestingPro.
In other recent news, Becton Dickinson reported its Q2 2025 earnings, showcasing a mixed performance. The company achieved an adjusted earnings per share (EPS) of $3.35, surpassing the forecast of $3.28, but revenue fell short at $5.27 billion against the anticipated $5.35 billion. Despite the revenue miss, the company highlighted its strategic investments in new product launches and U.S. manufacturing. Becton Dickinson also announced plans to invest $2.5 billion in U.S. manufacturing over the next five years. Analyst firms have noted the company’s ongoing challenges, including procurement pressures in China and research funding cuts. The company projects full-year revenue between $21.8 billion and $21.9 billion, with adjusted EPS guidance of $14.34 to $14.6. Becton Dickinson remains optimistic about organic growth improvements in the coming quarters.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.